NeuroOne (NMTC) schedules 2026 shareholder meeting and Rule 14a-8 cutoff

Q: What is the deadline for NMTC stockholder proposals under Rule 14a-8 for 2026?

Stockholder proposals under Rule 14a-8 for NeuroOne’s 2026 annual meeting must be received by the company’s Secretary by March 4, 2026 . The proposals must be delivered to NeuroOne’s principal executive offices to be considered for inclusion in the proxy materials.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

NeuroOne Medical Technologies Corporation set April 3, 2026 as the date for its 2026 annual meeting of stockholders. The company will provide the exact time, location, and voting items in a future proxy statement.

Because this date is more than 30 days later than the prior year’s meeting anniversary, stockholder proposals seeking inclusion in the 2026 proxy materials under Rule 14a-8 must be received at the company’s principal executive offices by March 4, 2026.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Understanding 8-K Material Events →

02/25/2026 - 04:30 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): February 25, 2026

NeuroOne Medical Technologies Corporation

(Exact name of registrant as specified in its charter)

Delaware

001-40439

27-0863354

(State or other jurisdiction

of incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

7599 Anagram Dr., Eden Prairie, MN 55344

(Address of principal executive offices and zip code)

952-426-1383

(Registrant’s telephone number including area code)

(Registrant’s former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		NMTC		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Items.

The Board of Directors of NeuroOne Medical Technologies Corporation (the “Company”) has established April 3, 2026 as the date of the Company’s 2026 annual meeting of stockholders (the “2026 Annual Meeting”). The Company plans to publish additional details regarding the exact time, location and matters to be voted on at the 2026 Annual Meeting in the Company’s proxy statement for the 2026 Annual Meeting.

Because the date of the 2026 Annual Meeting will change by more than 30 calendar days from the anniversary date of the Company’s 2025 annual meeting of stockholders, the Company has set a deadline for the receipt of stockholder proposals submitted pursuant to Rule 14a-8 under the Securities Exchange Act of 1934, as amended (“Rule 14a-8”) for inclusion in the Company’s proxy materials relating to the 2026 Annual Meeting. In order for a proposal under Rule 14a-8 to be timely, it must be received by the Company’s Secretary at the principal executive offices of the Company by March 4, 2026, which the Company has determined to be a reasonable time before the Company’s proxy materials are due to be printed and sent.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	NEUROONE MEDICAL TECHNOLOGIES CORPORATION
Dated: February 25, 2026
	By:	/s/ David Rosa
		David Rosa
		Chief Executive Officer

Source: View Original Filing on SEC EDGAR

FAQ

When is NeuroOne Medical Technologies (NMTC) holding its 2026 annual meeting?

NeuroOne Medical Technologies plans to hold its 2026 annual meeting of stockholders on April 3, 2026. The company will later provide the exact time, location, and agenda items in its proxy statement for the 2026 annual meeting.

What is the deadline for NMTC stockholder proposals under Rule 14a-8 for 2026?

Stockholder proposals under Rule 14a-8 for NeuroOne’s 2026 annual meeting must be received by the company’s Secretary by March 4, 2026. The proposals must be delivered to NeuroOne’s principal executive offices to be considered for inclusion in the proxy materials.

Why did NeuroOne (NMTC) set a Rule 14a-8 deadline for the 2026 annual meeting?

NeuroOne set a Rule 14a-8 deadline because the 2026 annual meeting date will differ by more than 30 days from the 2025 meeting’s anniversary. This timing change requires establishing a reasonable cut-off for including eligible stockholder proposals in the 2026 proxy materials.

Where must NMTC stockholders send Rule 14a-8 proposals for the 2026 meeting?

Rule 14a-8 proposals for NeuroOne’s 2026 annual meeting must be sent to the company’s Secretary at its principal executive offices. Proposals must arrive by March 4, 2026 to be considered for inclusion in the 2026 proxy statement.

Will NeuroOne (NMTC) disclose the agenda for the 2026 annual meeting now?

The agenda is not yet detailed. NeuroOne plans to publish additional information on the exact time, location, and matters to be voted on in its forthcoming proxy statement for the 2026 annual meeting of stockholders.

Filing Exhibits & Attachments

3 documents